Drug intelligence / Profile preview

normal saline + lidocaine + dexmedetomidine

Development stage
Unknown
Lead developer
Fresenius Kabi
Modality
Small Molecules
Administration
Intravenous, Local Infiltration, Nebulized, Regional Block
01

Overview

A combination formulation of **normal saline**, **lidocaine**, and **dexmedetomidine** used for intravenous or local infusion/administration, primarily in perioperative or procedural settings. **Lidocaine** acts as a sodium channel blocker providing local anesthetic and antiarrhythmic effects. **Dexmedetomidine** is a highly selective alpha-2 adrenergic agonist, providing sedation, analgesia, and sympatholytic effects. **Normal saline** serves as the vehicle/diluent for the active drugs. The combination is investigated and utilized for reducing perioperative oxidative stress, minimizing postoperative nausea and vomiting, stabilizing hemodynamics, and providing enhanced analgesia and sedation in various surgical and anesthesia contexts[1][2][3][6][7][8].

02

Targets

ADRA2A (α2A)SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)

Beyond the preview

Go deeper on normal saline + lidocaine + dexmedetomidine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on normal saline + lidocaine + dexmedetomidine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call